Related Experiment Video

Updated: Dec 12, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.6K

The Evolving Landscape of HER2-Directed Breast Cancer Therapy

Juan Luis Gomez Marti1, Tara Hyder2, Azadeh Nasrazadani3

  • 1Department of Pathology, University of Pittsburgh School of Medicine, 3550 Terrace St, Pittsburgh, PA, 15213, USA.

Current Treatment Options in Oncology
|August 9, 2020
PubMed
Abstract

Insights

Management of HER2+ breast cancer now uses dual blockade with trastuzumab and pertuzumab. Novel agents are emerging for recurrent and resistant HER2+ breast cancer, offering new treatment avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Human Epidermal growth factor Receptor 2 (HER2) positive breast cancer management has seen significant evolution.
  • HER2 targeting has moved beyond single-receptor focus to multifaceted strategies.

Purpose of the Study:

  • To review the current standard of care for HER2+ breast cancer.
  • To discuss the efficacy of T-DM1 in specific patient populations.
  • To highlight emerging novel agents and their mechanisms of action.

Main Methods:

  • Review of current clinical practices and therapeutic approvals.
  • Analysis of data regarding T-DM1 efficacy in residual disease.
  • Exploration of upcoming therapeutic strategies for HER2+ breast cancer.

Main Results:

  • Dual HER2 blockade with trastuzumab and pertuzumab is the current standard of care in adjuvant and metastatic settings.
  • T-DM1 demonstrates significant efficacy in patients with residual disease post-neoadjuvant therapy.
  • Several novel agents with diverse mechanisms are in development for later lines of therapy.

Conclusions:

  • The treatment landscape for HER2+ breast cancer is dynamic, with established dual blockade and promising new therapies.
  • Continued research is crucial for addressing resistance and improving outcomes in HER2+ breast cancer.
  • Future directions involve novel agents targeting HER2 through various pathways.
Keywords:
Antibody-drug conjugatesBreast cancerHER2Monoclonal antibodiesTargeted therapiesTyrosine kinase inhibitors

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K